Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a Mastercard stock analysis & discuss the risks and upside potential of MA and Visa stock

2 extracted signals · 2 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
25 Feb 2026, 00:19 UTC
Recorded by Tahlil Plus
18 May 2026, 20:24 UTC
Video preview for Friends! In this video, I'm going to do a Mastercard stock analysis & discuss the risks and upside potential of MA and Visa stock
Source overview

AI-generated source summary

The analysis focuses on Visa (V) and Mastercard (MA) stock performance, highlighting their recent downturns. Visa is trading at 306.52 USD, down 11.53% year-to-date. Mastercard is trading at 496.03 USD, down 5.77% today and 11.92% year-to-date. The speaker suggests that both stocks are in a bearish trend, with potential downside targets for Visa at $294 (23x earnings) and for Mastercard at $478 (25x earnings). The speaker also notes that Visa's earnings growth is projected to be around 13% annually for the next 2-3 years, while Mastercard's is expected to be faster at 15-16%. Despite this, the speaker prefers Visa due to its lower multiples and solid business model, but is waiting for a better entry point as other stocks are declining.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
2
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
2
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
2 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  4. Market predictions extracted

    2 eligible signals linked to this case.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail